Abstract:BACKGROUND: Fibrosing interstitial lung disease (ILD) encompasses more than 200 diverse pulmonary disorders, of which up to 40% become progressive. The 4 underlying ILD types most likely to result in progression are unclassified ILD/idiopathic interstitial pneumonia (IIP), autoimmune ILDs, exposure-related ILD/hypersensitivity pneumonitis, and sarcoidosis.OBJECTIVE: To compare health care resource utilization (HCRU) and costs among patients with fibrosing ILD that has progressed ("progressive" fibrosing cohort) vs patients whose fibrosis did not meet criteria set for progression ("not yet progressed" cohort).METHODS: This was a noninterventional study of commercial enrollees and Medicare Advantage with Part D beneficiaries, which used administrative claims data for the period from October 1, 2015, through May 31, 2021. Adult patients (aged ≥18 years) with fibrosing ILD and 12 months of continuous health plan enrollment were included. Patients with idiopathic pulmonary fibrosis, baseline ILD diagnoses, or missing demographic data were excluded. Patients were first classified according to the underlying type of fibrosing ILD. For statistical analyses of outcomes, 2 cohorts were compared within each subtype: progressive fibrosing ILD vs not yet progressed ILD. The final study population included propensity score-matched (PSM) patients (1:1) based on pre-ILD baseline demographic and clinical characteristics. HCRU categories included inpatient hospitalization counts and the number of inpatient days and total costs (in 2021 US dollars), analyzed descriptively and weighted by the per-patient-per-month cost. Lin's regression was used to predict 12-month total cost estimates for comparison by cohort.RESULTS: The distribution by underlying conditions was as follows: autoimmune ILD (n = 4,156), HP (n = 8,181), sarcoidosis (n = 775), and unclassified ILD/IIP (n = 18,635). After PSM, pre-ILD baseline variables were generally well balanced between the progressive and not yet progressed fibrosing ILD cohorts. For all underlying subtypes of ILD, patients in the progressive cohort had significantly more utilization and higher costs compared with patients in the not yet progressed cohort. Progressive cohorts had significantly higher adjusted rates of inpatient days among patients with at least 1 inpatient stay compared with the not yet progressed cohorts (all <i>P</i> < 0.01). In addition, the progressive cohorts had significantly higher adjusted 12-month total costs, with the differences ranging from $24,493 to $55,072 (all comparisons <i>P</i> < 0.001).CONCLUSIONS: Irrespective of underlying ILD type, patients with progressive fibrosing ILD had significantly increased HCRU and cost relative to those whose fibrosing ILD had not yet progressed.

Design and baseline characteristics of the ILD-PRO registry in patients with progressive pulmonary fibrosis

Predictors of Progression in Idiopathic Inflammatory Myopathies with Interstitial Lung Disease

Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)

Pursuing Clinical Predictors and Biomarkers for Progression in ILD: Analysis of the Pulmonary Fibrosis Foundation (PFF) Registry

Proteomic Biomarkers of Progressive Fibrosing Interstitial Lung Disease: a Multicentre Cohort Analysis.

Proportion and predictors of FVC decline in patients with interstitial lung disease

Idiopathic Pulmonary Fibrosis in the United Kingdom: Findings from the first decade of the largest single-country IPF Registry

Predicting progressive phenotype in patients with fibrotic interstitial lung disease

Prevalence and risk factors of progressive pulmonary fibrosis(PPF) in patients with Interstitial Lung Disease(ILD) in a tertiary care center in India

The natural history of progressive fibrosing interstitial lung diseases

Idiopathic Pulmonary Fibrosis Registry China study (PORTRAY): protocol for a prospective, multicentre registry study

Risk factors for progression of pulmonary fibrosis: a single-centered, retrospective study

Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management

Progression of fibrosing interstitial lung disease

Predictors of Progression in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Single-Center Retrospective Study from China

A study on the prevalence and prognosis of progressive pulmonary fibrosis: A retrospective observational study

Lung function trajectory in progressive fibrosing interstitial lung disease

Health care costs and utilization of progressive fibrosing lung disease by underlying interstitial lung disease type

Diagnostic and prognostic biomarkers for progressive fibrosing interstitial lung disease

Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions

Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression